Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

• by Ana-Cristina Almansa-García, Angela Armento, Bowen Cao, Anne-Sophie Petremann-Dumé, Stefano Salmaso, Paolo Caliceti, Cristine Henes, Sylvie Bolz, Ellen Kilger, Daniela Süsskind, Marius Ueffing, Blanca Arango-Gonzalez

• January 10, 2026

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

• by Kerri Miller

• May 7, 2026

• 3 min

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

• by Andrea Surnit

• May 11, 2026

• 3 min

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

• by Kathryn Wighton

• April 7, 2026

• 3 min